TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36361001
Drug: Conventional occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional occupational therapy (OT)
Study: 34575292
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of clonidine 1 µg/kg and normal saline 0.9% (Group 2)
Study: 34575292
Drug: Lidocaine 2%
Normalized name: LIDOCAINE 2% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% with 1:200,000 epinephrine plus 2 mL of normal saline 0.9% (Group 1)
Study: 33333767
Drug: Bioactive compounds
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioactive compounds enriched infant formula (EF)
Study: 34358486
Drug: Probiotics (Bacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Bacillus coagulans MY01 and Bacillus subtilis MY02, 2·5 × 10^9 colony-forming units per capsule, consumed twice per day for 8 weeks)
Study: 34358486
Drug: Placebo (consumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (consumed twice per day for 8 weeks)
Study: 32191532
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 µg/DRSP 3 mg
Study: 32191532
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 µg/CMA 2 mg
Study: 32191532
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 µg/DNG 2 mg
Study: 37489374
Drug: Sirolimus treatment
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus treatment
Study: 32213105
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine at 6.5 mg/kg once every 3 weeks
Study: 32213105
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine at 1.8 mg/kg once per week
Study: 32213105
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine at 2.2 mg/kg once per week
Study: 32213105
Drug: Anetumab ravtansine
Normalized name: Anetumab ravtansine
DrugBank: Anetumab ravtansine (DB14809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetumab ravtansine (various doses)
Study: 32603560
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with aripiprazole
Study: 32603560
Drug: Augmentation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation with bupropion
Study: 34913294
Drug: Letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (2.5 mg twice daily)
Study: 34913294
Drug: Ganirelix acetate
Normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix acetate (0.25 mg subcutaneously daily)
Study: 33491323
Drug: 1.5 oz
Normalized name: {1 (1.5 OZ Hydrocortisone 1 % Topical Gel) / 1 (60 GM Ketoconazole 2 % Topical Cream) } Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 oz of almonds daily for 12 weeks
Study: 33491323
Drug: 1.8 oz
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL LIQUID [Hand Sanitizer Original 1.8 oz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 oz of pretzels daily for 12 weeks
Study: 32605655
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment group
Study: 32605655
Drug: Orthodontic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orthodontic treatment group
Study: 35037386
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml minoxidil for external use twice a day
Study: 35037386
Drug: 3500 IU
Normalized name: Lactic Acid/Vitamin E 10%-3500 IU/30 GM Topical application Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3500 IU basic fibroblast growth factor (bFGF) and 1 ml minoxidil for external use twice a day
Study: 33161036
Drug: Microneedle (MN)
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle (MN) patch
Study: 33161036
Drug: Microneedle patch
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle patch with needles laying flat (negative control)
Study: 35676335
Drug: Nicotine transdermal
Normalized name: NICOTINE TRANSDERMAL KIT
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine transdermal patch (14 mg daily)
Study: 36245011
Drug: Weekly DPCP
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly DPCP application
Study: 33407828
Drug: Hochu‐ekki‐to (HET)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hochu‐ekki‐to (HET) - 9 tablets, 2 times per day for 8 weeks
Study: 33407828
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 9 tablets, 2 times per day for 8 weeks
Study: 33155034
Drug: SaLeish vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SaLeish vaccine (fusion protein of SP15 and LeIF)
Study: 36179438
Drug: Online cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online cognitive behavioral therapy (CBT) program
Study: 33823560
Drug: Therapeutic-dose low
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose low molecular weight heparin (LMWH) - enoxaparin 1 mg/kg SQ/BID (CrCl ≥ 30 ml/min) or 0.5 mg/kg (CrCl 15-30 ml/min)
Study: 33823560
Drug: Prophylactic/intermediate-dose LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic/intermediate-dose LMWH or unfractionated heparin (UFH)
Study: 33823560
Drug: Therapeutic-dose LMWH
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic-dose LMWH
Study: 39338117
Drug: Manual Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual Therapy
Study: 39076222
Drug: Tocovid capsules
Normalized name: dimethicone
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tocovid capsules
Study: 36272277
Drug: Extended infusion
Normalized name: Extended Infusion Set 6mm Cannula 23" Tubing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended infusion of ampicillin/sulbactam (infused over 4 hours)
Study: 36272277
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion of ampicillin/sulbactam (infused over 30 minutes)
Study: 35396602
Drug: Domagrozumab (myostatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domagrozumab (myostatin inhibitor)
Study: 34292820
Drug: Liposomal bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine (LB) 266 mg (20 mL)
Study: 32217791
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron (PILL)
Study: 32217791
Drug: Transdermal iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal iron (PATCH)
Study: 34903440
Drug: Routine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatments and care process (Control group).
Study: 32385167
Drug: 12.7 g
Normalized name: potassium chloride 12.7 gram HEMODIALYS POWDER IN PACKET (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.7 g of MSG
Study: 34206175
Drug: Resistance training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistance training (body weight, elastic bands, water canes) twice per week for eight months
Study: 33051340
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Stereotactic Body Radiation Therapy (SBRT; 50 Gy in 4 fractions)
Study: 33051340
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Traditional Radiation Therapy (45 Gy in 15 fractions)
Study: 32838470
Drug: Non-vitamin K
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-vitamin K dependent oral anticoagulants (NOACs)
Study: 33677049
Drug: Whole-lung low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole-lung low-dose radiation therapy (LDRT) 1 Gy
Study: 33677049
Drug: Whole-lung low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whole-lung low-dose radiation therapy (LDRT)
Study: 32067817
Drug: EV71 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EV71 vaccine from Institute of Medical Biology Chinese Academy of Medical Sciences (CAMS) for the first dose and Sinovac vaccine for the second dose (Group D)
Study: 32067817
Drug: Single vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single vaccine from one manufacturer (two groups)
Study: 32067817
Drug: Mixed schedules
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed schedules using vaccines from two manufacturers (two groups)
Study: 35446282
Drug: Compound Training
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Training (CPD)
Study: 32268344
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg of haloperidol
Study: 34187530
Drug: LPV (Vt
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV (Vt = 6 ml/kg of ideal body weight, respiratory rate initially set at 16 breaths/min, PEEP at 5 cmH2O, recruitment manoeuvre applied)
Study: 34187530
Drug: Control (Vt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Vt = 10 ml/kg of ideal body weight, respiratory rate initially set at 6–8 breaths/min, no PEEP, no recruitment manoeuvre)
Study: 33487255
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (650 mg DHA, 3 times/week, post-HD session)
Study: 32507538
Drug: Cholecalciferol (vitamin
Normalized name: cholecalciferol (vitamin D3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol (vitamin D3) 4,000 IU or 7,000 IU daily for 6 and 12 weeks
Study: 34397393
Drug: Internet-based warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based warfarin management
Study: 34397393
Drug: Conventional warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional warfarin management
Study: 36892753
Drug: Risankizumab 180
Normalized name: RISANKIZUMAB 180 mg in 1.2 mL SUBCUTANEOUS INJECTION, SOLUTION [Skyrizi]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risankizumab 180 mg
Study: 35710572
Drug: Heterologous boost
Normalized name: BOOST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous boost COVID‐19 vaccine regimens (intervention groups 1–4)
Study: 32721007
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogen (CEE) alone
Study: 32721007
Drug: 0.625 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.625 mg/d of conjugated equine estrogen (CEE) plus 2.5 mg/d of medroxyprogesterone acetate (MPA)
Study: 35489363
Drug: Lenvatinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (oral 20 mg per day) plus Pembrolizumab (intravenous 200 mg every 21 days)
Study: 35489363
Drug: Sunitinib (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (oral 50 mg per day, 4 weeks on followed by 2 weeks off)
Study: 33942376
Drug: Inosine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosine (active treatment)
Study: 33581174
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg MET409
Study: 33581174
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg MET409
Study: 32648183
Drug: Laparoscopic resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic resection for rectal cancer
Study: 32633541
Drug: All antipsychotics
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All antipsychotics combined
Study: 35557513
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (CDDP 20 pills three times per day)
Study: 35557513
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment group (10 pills CDDP and 10 pills placebo three times per day)
Study: 33059380
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with 0.5% tetracaine-HCl ophthalmic solution applied three times at 30-second intervals after wound closure
Study: 33059380
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical anaesthesia (control group)
Study: 35144570
Drug: Inquiry‐Based Stress
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inquiry‐Based Stress Reduction counseling session (2 hours weekly for 6 weeks)
Study: 33244872
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) alpha1‐PI[h] therapy (90 or 180 mg/kg weekly for 13 or 26 weeks)
Study: 33244872
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) alpha1‐PI[h] therapy
Study: 35841457
Drug: Mongersen (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mongersen (oral antisense oligonucleotide targeting Smad7)
Study: 35077474
Drug: rasagiline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline (1 mg/day)
Study: 35077474
Drug: rasagiline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rasagiline (0.5 mg/day)
Study: 33757474
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cranberry proanthocyanidin extract (2 × 18.5 mg daily, n = 72)
Study: 33757474
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose cranberry proanthocyanidin extract (2 × 1 mg daily, n = 73)
Study: 33757474
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose cranberry proanthocyanidin extract
Study: 32833477
Drug: Mindfulness based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness based cognitive therapy ‐ perinatal depression (MBCT‐PD)
Study: 35139937
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma gel
Study: 36319057
Drug: Methenamine hippurate
Normalized name: Methenamine Hippurate
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine hippurate 1 g, two times per day for 6 months
Study: 36319057
Drug: Placebo tablets,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets, two times per day for 6 months
Study: 33109586
Drug: α-type-1 DC
Normalized name: WHITE SPIRIT TYPE 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: α-type-1 DC vaccine
Study: 32245508
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydroxychloroquine (HCQ) for 4 weeks in the START block, followed by a switch to active drug for the placebo group.
Study: 37246674
Drug: Same Arm
Normalized name: SAMe
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same Arm Movement Therapy for 8 weeks (45 min supervised sessions 3 times a week and structured independent sessions twice a week)
Study: 37246674
Drug: Constraint Induced
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constraint Induced Movement Therapy for 8 weeks (2 hours per day, 5 days a week, with restriction of the non-affected extremity for 10 hours a day)
Study: 32532583
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine triphosphate (ATP) infusion at 210 μg/kg/min (IVATP210)
Study: 32532583
Drug: Intravenous adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous adenosine triphosphate (ATP) infusion at 150 μg/kg/min (IVATP150)
Study: 32532583
Drug: Intracoronary administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary administration of nicorandil 2 mg (ICNIC2mg)
Study: 32304185
Drug: Relaxation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relaxation therapy (RT) and information only (Co)
Study: 32304185
Drug: Supplementary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary treatment (ST)
Study: 36424550
Drug: Intervention (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (daily automated flags in CHORUS™)
Study: 32660748
Drug: Atezolizumab vs
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab vs Chemotherapy
Study: 33513242
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies (Nabs) measured using a lentiviral vector‐based SARS‐CoV‐2 neutralization assay
Study: 33513242
Drug: Neutralizing antibodies
Normalized name: DentiCare Neutral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing antibodies (Nabs) in patients with diabetes
Study: 33950945
Drug: Placebo acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo acupuncture (placebo treatment using a similarly designed press tack needle without the needle element)
Study: 35305222
Drug: CBT4CBT‐Spanish (culturally
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT4CBT‐Spanish (culturally adapted Spanish‐language version of web‐based cognitive behavioral therapy)
Study: 34489516
Drug: Nurse-led, telephone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led, telephone-based follow-up including medical titration
Study: 33236646
Drug: SIC +
Normalized name: TRACH CANNULA,SZ 8 SHLY #8-SIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIC + Octagam (30 g/day for 5 days)
Study: 35143095
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (thrombectomy preceded by intravenous alteplase)
Study: 34735963
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) at doses of 8 mg and 12 mg/day
Study: 34735963
Drug: Perampanel (PER)
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Perampanel (PER) at doses of 2 mg and 4 mg/day
Study: 32311925
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) treatment with a diode laser emitting at 808 nm, 100 mW, for 40 seconds per site, 20 sites irradiated weekly for 4 weeks
Study: 32311925
Drug: Placebo PBM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo PBM treatment
Study: 35460304
Drug: Photobiomodulation (PBM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation (PBM) in addition to conventional symptomatic treatment
Study: 34618482
Drug: Physical and/or
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical and/or sexual abuse treatment (PSA‐T)
Study: 32596729
Drug: Potassium supplement
Normalized name: Potassium supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium supplement (90 mmol/day)
Study: 32184185
Drug: Minesapride 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 40 mg
Study: 32087003
Drug: Minesapride 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minesapride 120 mg
Study: 35829629
Drug: Chemotherapy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy and radiation therapy
Study: 35477634
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ketamine (0.5 mg/kg, infused over 40 minutes)
Study: 35477634
Drug: Intranasal (IN)
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal (IN) esketamine (56/84 mg)
Study: 32303436
Drug: Edetate disodium
Normalized name: Edetate Disodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edetate disodium chelation therapy (40 infusions of a 500 mL solution)
Study: 33472420
Drug: Web ORLA®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web ORLA® (Oral Reading for Language in Aphasia)
Study: 32537276
Drug: Conventional physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional physical therapy with visceral mobilization
Study: 34265777
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy for Insomnia (CBTi) followed by Cognitive Processing Therapy (CPT)
Study: 35430325
Drug: Theta tACS
Normalized name: Coptis teeta root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theta tACS (20 minutes) during daily multitasking training
Study: 35430325
Drug: Delta tACS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delta tACS (20 minutes) during daily multitasking training
Study: 35175905
Drug: 6-month all-oral
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month all-oral regimen including levofloxacin, bedaquiline, and linezolid
Study: 32001833
Drug: Intraperitoneal carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal carboplatin (AUC = 6) and intravenous paclitaxel (80 mg/m2) administered on days 1, 8, and 15.
Study: 32713466
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (single preoperative dose)
Study: 33310052
Drug: Progressive relaxation
Normalized name: Relax-DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progressive relaxation exercises (self-administered via CD for two menstrual cycles)
Study: 32209248
Drug: MenACYW-TT co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACYW-TT co-administered with Tdap and HPV4
Study: 32209248
Drug: Tdap and
Normalized name: metformin and ertugliflozin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tdap and HPV4 vaccines alone
Study: 34617974
Drug: Lifitegrast ophthalmic
Normalized name: lifitegrast ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifitegrast ophthalmic solution, 5.0%, twice daily for 84 days